Table 3.
Listing of adverse events. Safety analysis set
| Item | Grade 1–2 n (%) |
Grade ≥ 3 n (%) |
|---|---|---|
| Any adverse event | 15 (88.2%) | 0 |
| Vomiting | 3 (17.6%) | 0 |
| Abdominal Pain | 2 (11.8%) | 0 |
| Ascites | 1 (5.9%) | 0 |
| Dyspepsia | 1 (5.9%) | 0 |
| Nausea | 1 (5.9%) | 0 |
| Paresthesia | 2 (11.8%) | 0 |
| Headache | 1 (5.9%) | 0 |
| Dizziness | 1 (5.9%) | 0 |
| Seizure | 1 (5.9%) | 0 |
| Anemia | 4 (23.5%) | 0 |
| Platelet count decreased | 1 (5.9%) | 0 |
| Fatigue | 4 (23.5%) | 0 |
| Skin infection | 2 (11.8%) | 0 |
| Agitation | 1 (5.9%) | 0 |
| Confusion | 1 (5.9%) | 0 |
| Pain of skin | 1 (5.9%) | 0 |
| Pruritus | 1 (5.9%) | 0 |
| Hypoxia | 1 (5.9%) | 0 |
| Creatinine increased | 1 (5.9%) | 0 |
| Hyperglicemia | 1 (5.9%) | 0 |
| Neck pain | 1 (5.9%) | 0 |
| Pain in extremity | 1 (5.9%) | 0 |
| Tumor pain | 1 (5.9%) | 0 |
n = number of subjects
percetages are based on the number of subjects within each cohort